Drug Profile

CIM 102

Alternative Names: CIM-102

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CiMaas
Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Acute myeloid leukaemia

Most Recent Events

28 May 2025 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Netherlands (Parenteral)
31 Jan 2022 CiMaas plans a pivotal phase IIb trial for non-small cell lung cancer (Metastatic disease) in USA in 2025 (CiMaas pipeline, January 2022)
28 Apr 2021 CiMaas plans a phase IIa trial for Acute myeloid leukaemia in the beginning of the year 2023 (CiMaas pipeline, April 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com